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Abstract 
 
Rift Valley fever virus (RVFV) is an emerging infectious disease of domesticated livestock 
that is endemic to many regions of Africa and is spread by multiple mosquito species. RVFV 
epizootic outbreaks commonly affect sheep and cattle, resulting in hepatic disease and 
hemorrhagic fever. One of the most devastating characteristics seen in previous outbreaks are 
among pregnant livestock which experience “abortion storms” wherein the virus induces 
abortogenic rates of 90-100%. While human RVF carries a small risk of mortality, RVFV is of 
great public health significance to women during pregnancy. An association has been 
demonstrated between women who are infected with RVFV and increased likelihood of late term 
miscarriage. Thus, RVFV infection in pregnant women carries the potential for vertical 
transmission to the child. Vertical transmission cases have been documented in naturally occurring 
outbreaks. Our lab has also demonstrated vertical transmission in a pregnant rat model of RVFV 
congenital infection. Pregnant rats were inoculated with wildtype RVFV subcutaneously, 
mimicking the mosquito bite transmission seen in natural infections. Type III interferons, the IFN-
 family of proteins, are a group of innate, antiviral molecules that function in modulating host 
immune responses to viral infection at epithelial barriers, including the placenta. Unlike type I 
interferons which elicit antiviral responses in all nucleated cells, which express the IFNAR1 
receptor, type III interferons elicit a more localized innate antiviral response, with receptors for 
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IFN- proteins only found on barrier epithelial cells. Previous work has examined a type III 
interferon, IFN-1, and its ability to confer protection at the placental barrier during Zika virus 
infection. Primary human trophoblasts, the barrier cells of the placenta, constitutively release IFN-
 which protects trophoblast and non-trophoblast cells from Zika virus infection, suggesting the 
virus must use alternative pathways to cross the placental barrier. The research presented herein 
represents the first investigationsperformed to define the possible modulatory effects of type III 
IFNs on RVFV pathogenesis.  
We performed experiments in vitro in cell lines mimicking the hepatic and placental tropism 
for RVFV infections. Exogenous treatment with interferon revealed that type III IFN can reduce viral 
titers in infected cells in a time- and cell-dependent manner. Further, cells infected with wildtype 
RVFV or RVFV-ΔNSs/GFP exhibited modulated IFN stimulated gene (ISG) expression. The research 
presented herein represents the first investigations performed to define the possible modulatory effects 
of type III IFNs on RVFV pathogenesis. 
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1.0 Introduction 
Rift Valley fever virus (RVFV) is an emerging infectious disease endemic to many regions 
of Africa. It is primarily a veterinary disease with occasional zoonotic events and is spread by 
multiple mosquito species (1). It is the causative agent of Rift Valley fever (RVF). Formerly a 
member of the Bunyaviridae family of viruses, RVFV has recently been reclassified within the 
Phenuiviridae family of viruses, genus Phlebovirus, within the now expanded order of 
Bunyavirales (2). It is a single-stranded, enveloped RNA virus with a tripartite segmented genome 
encoding two negative sense segments large (L) and medium (M), as well as a small (S) ambisense 
segment (3). RVFV encodes for 7 proteins, 4 structural and 3 nonstructural (3). The structural 
proteins are RNA polymerase (L), glycoprotein Gn (M), glycoprotein Gc (M), and nucleocapsid 
protein (S) (3). The nonstructural proteins are NSm1 (M), NSm2 (M) and NSs (S) (3). NSs is the 
major virulence factor for the virus.  
 
Figure 1: Schematic of RVFV genome structure and coding regions, with coding strategy indicated by arrows. 
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Rift Valley fever virus was first identified in 1930, during an outbreak in sheep and cattle 
in Kenya’s Rift Valley (4). The virus is primarily a veterinary disease, causing a mortality rate of 
10-20% among domesticated ruminants (5). Clinical manifestations in humans include 
hemorrhagic fever, hepatic disease and encephalitis. The main disease manifestation in ruminants 
is hepatic disease. One of the most devastating characteristics of RVF are among pregnant 
livestock which experience “abortion storms” wherein the virus can induce abortogenic rates of 
90-100% (6, 7). An association has recently been demonstrated between women who are infected 
with RVFV and an increased likelihood of late term miscarriage (8). RVFV infection in pregnant 
women may also carry the potential for vertical transmission to the child. There are a few 
documented cases of vertical transmission in naturally occurring outbreaks (9). Previous data in 
our lab has also demonstrated vertical transmission using a rat model (10).  
1.1 Rift Valley Fever Virus 
1.1.1  Epidemiology 
RVFV was first isolated during an epizootic outbreak in the Great Rift Valley of Kenya 
(11). Major rainfall followed by largescale fatal illness in lambs and febrile illness among the 
surrounding human population precipitated the discovery of RVFV by local veterinarians (11). 
Since its initial outbreak, the geographic range of confirmed RVFV outbreaks has steadily 
increased, growing to include South Africa, Madagascar, Eastern Africa and into Egypt, most 
recently expanding into the Arabian Peninsula with outbreaks in Saudi Arabia and Yemen (11).  
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RVFV is an arbovirus, spread primarily by mosquito-bite (12). RVFV replicates in a life 
cycle common to viruses in the Phlebovirus genus. As an arbovirus, RVFV utilizes mosquito 
species to mature and spread to other host species. The virus can lie dormant in desiccated 
mosquito eggs during dry periods. In subsequent periods of heavy rainfall, blooms in the mosquito 
population, already infected with RVFV, can contribute to enzootic and epizootic outbreaks, as 
was the case in the 1930 outbreak during which RVFV was first identified (11). RVFV has been 
found in numerous mosquito species including widespread genera such as Aedes and Culex 
mosquitoes (13).  
RVFV infection in humans is possible from working with infected animals or tissues as 
well as infection via aerosol exposure (14-16).  To date, no human-to-human transmission has 
been documented. 
The history of RVFV human epidemiology includes a series of outbreaks with disparate 
scales, both in terms of the size of the outbreaks and the range of human outcomes. The 1977 
Egyptian outbreak caused an estimated 18,000-200,000 human infections, and 598 disease-
attributable deaths (11, 15). Infected individuals in this outbreak predominantly presented with 
undifferentiated febrile illness (17).   
In 2000, Saudi Arabia experienced a smaller but more clinically severe outbreak, with 245 
human deaths out of 834 confirmed cases and thousands of livestock succumbing to disease (11, 
18). Human clinical and laboratory features from the Saudi Arabian outbreak included fever, 
jaundice, and neurological symptoms as well as 98% of tested cases characterized by elevated liver 
enzymes, highlighting RVFV hepatic tropism. Hemorrhage, neurological symptoms and jaundice 
were all independently associated with increased mortality rate. 
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Among livestock in the same Saudi Arabian outbreak, an estimated 40,000 animals, 
primarily sheep and goats succumbed to RVFV infection themselves or experienced spontaneous 
abortion. Mass ruminant abortion storms are a hallmark of epizootic events and often precede 
RVFV human cases (11, 18). 
Over time, RVFV has spread steadily throughout Africa, with major outbreaks in both 
humans and livestock being recorded in Sudan, Somalia, Kenya, Tanzania, Zambia, Zimbabwe, 
South Africa, Senegal, Mauritania, Yemen, and even Madagascar (19). Expanded geographic 
distribution in Africa and beyond is expected to continue growing concomitant with increasing 
global temperatures due to climate change. 
1.1.2  Clinical RVF Disease in Humans 
The most common clinical manifestation of RVFV infection in humans is a self-limiting 
febrile illness (20, 21). The virus has a 4-6-day incubation period after which begin with chills, 
dizziness, malaise, headaches, and nausea. After these initial symptoms, fever typically occurs for 
between 4 and 10 days (11). The vast majority of infections are limited to this level of severity, 
however 1-2% of human infections present with more complicated and severe outcomes (20). The 
most common of the more severe outcomes can include ocular RVFV infection, hemorrhagic 
fever, and encephalitis.  
Ocular RVFV infection can cause blindness, either concurrent with the presentation of 
initial febrile symptoms, or even up to months after infection, a phenomenon in common with 
other viral infections occurring in immune-privileged sites where viral flareups long after the 
primary infection can accompany symptoms and new complications (22).  
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Hemorrhagic fever occurs in the most fatal cases, often with little warning. In addition to 
the symptoms common in early RVFV infection, infected individuals can also experience bleeding 
in the gums and gastrointestinal tract, jaundice, and a reduction in hemoglobin and platelet counts. 
Direct hemorrhage is not necessary for a hemorrhagic fever distinction and the most common 
cause of death in these cases is liver failure, typically within 3-6 days (20).  
Encephalitis in RVFV infections is accompanied by direct viral infection of the brain. The 
path the virus takes as well as the dynamics controlling this course of disease are unclear. 
Individuals progressing to encephalitic RVFV infection show symptoms common to neurological 
disorders and other encephalitic viruses including headaches, nausea, confusion and seizures (20).  
1.1.3  Prevention and Treatment 
No vaccines or therapeutic drugs are FDA-approved for Rift Valley fever virus (14). A few 
experimental therapeutics exist, albeit with significant side effects and questionable efficacy. The 
vaccines that exist for RVFV include attenuated live vaccines, some of which are licensed for use 
in livestock, but which carry with them documented teratogenic effects.  
The first live-attenuated vaccine was derived from the Smithburn strain of RVFV in 1949 
(23). The virus was attenuated by passaging in mouse brains 102 times, and was administered to 
livestock as a vaccine (24). The vaccine was refined in 1971 and sold as a “modified live virus 
vaccine” (MLVV), but despite its heavy attenuation, the virus had a high potential for reversion to 
wildtype virus in livestock (24). To use this vaccine in regions of Africa in which RVFV was not 
already endemic could essentially result in increasing the pace of the virus’ geographic spread in 
the likely event that the vaccine would revert to wildtype virus after administration into the 
livestock population.   
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The United States government began research on another RVFV vaccine candidate, labeled 
MP-12, after the 1977 outbreak in Egypt (24). Two clinical isolates from the Egyptian outbreak, 
ZH501 and ZH548, were serial passaged in the presence of 5-flourouracil to attenuate the virus 
via mutagenesis (23). The live attenuated mutant that resulted from ZH548 became the MP-12 
vaccine, which contained a myriad of deletions in all three segments of the virus (23). The MP-12 
strain was again teratogenic, although to a lesser degree than the Smithburn vaccine (25). Despite 
showing efficacy in preventing abortions in ewes during later pregnancy, a low rate of abortions 
occurred when the vaccine was administered early in pregnancy, as well as other adverse effects 
in calves born from vaccinated ewes (24, 25). Nevertheless, the US government needed a vaccine 
for their military personnel and did conduct a small experimental vaccination of 100 soldiers. MP-
12 proved to be safe and efficacious, though the FDA has never licensed the vaccine (24).  
Another vaccine candidate is Clone 13, isolated from a plaque from an infected individual 
in Central Africa (24). This vaccine strain has the majority of the NSs gene deleted, resulting in 
functional loss of the NSs protein, the major virulence factor in RVFV infections. Reversion is 
significantly hampered by the extent of the NSs deletion and Clone 13 remains a viable candidate 
for a veterinary vaccine, demonstrating efficacy and safety in trials (24).  
Finally, DDVax, a recombinant RVFV vaccine lacking both NSs and NSm virulence 
factors, has demonstrated protection against RVFV challenge in sheep, including during pregnancy 
(26). As of yet, the FDA has not approved it for use in humans.  
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1.2 Public Health Significance  
1.2.1 Endemic RVFV in Africa  
Outbreaks in endemic areas of Africa are sporadic but generally follow periods of heavy 
rainfall which result in blooms in the mosquito population. RVFV infections exhibit some 
seasonality but it remains difficult to predict outbreaks even in endemic areas.  
In addition to human morbidity and mortality due to RVFV infection, veterinary infections 
can drastically impact the livelihoods of those with livestock who have been affected. In Kenya, 
where the virus was originally discovered, livestock account for almost 90% of the pastoral 
economy (27). RVFV can effectively obliterate farmers’ livelihoods through a combination of 
directly killing off their livestock, inducing massive abortogenic rates destroying the next 
generation of livestock for which farmers could make a profit, and even through stigma attached 
to those animals that do survive the outbreak, essentially making whatever animals survive also 
unprofitable (27).  
This effect on the supply side of the economy in Kenya naturally has deleterious effects on 
other institutions, including butchers, meat markets, and slaughterhouses. Further, epidemics tend 
to inspire surrounding markets to refuse any products coming out of the affected area. During 
outbreaks in Africa, including the Arabian Peninsula, surrounding countries banned the import of 
meat from affected areas (27).  
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1.2.2 RVFV in the United States 
Closer to home, the United States is not immune to the potential for RVFV enzootic and 
epizootic transmission. Aedes and Culex mosquitos are the most common vectors for RVFV in 
Africa, but over 50 mosquito species have been shown to be capable of transmitting the virus, 
including in experiments with species found in North America (28). In addition to US livestock, 
white tailed deer have also been shown to be a competent host for the virus (29). With the 
continuing march of climate change and subsequent increases in habitable ranges for mosquito 
populations, RVFV stands to establish prolonged transmission and endemic status in much of the 
US, with a $50 billion dollar price tag to attempt to control the virus once it is established here 
(30). 
The spread of Zika virus in the Americas during 2015-2016 is evidence of the potential 
harm of mosquito-borne viruses increasing range. For a virus with similar congenital and 
neurological characteristics as RVFV, there were 1,000 confirmed cases of Zika infection in 
pregnant women (31).  
1.3 Animal Models 
1.3.1  Mice 
Mice are very susceptible to RVFV infection. The most common mouse used in animal 
research is the BALB/c strain. Mice infected with wildtype Rift Valley fever virus strains show 
symptoms in 2-3 days and typically die within 24 hours of symptom onset. Death from wildtype 
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RVFV in mice occurs within 3-5 days, with infected animals succumbing to fatal hepatitis 
regardless of exposure route or dose (32). Mice given attenuated RVFV with a deletion in the NSs 
gene (ΔNSs) via footpad injection results in subclinical disease, characterized by rapid antibody 
responses and robust T cell involvement. When given intranasally, RVFV-ΔNSs-infected mice 
develop lethal neurological disease in 7-9 days, providing a model of in vivo encephalitis (32). 
IFNAR-/- mice develop severe disease when exposed to attenuated RVFV strains due to their 
inability to mount interferon-driven antiviral responses (33).  
RVFV pathogenesis in mice mimics that of lambs, where the disease manifests as acute 
hepatitis with capacity to progress to encephalitis. Hemorrhagic fever does not occur in mouse 
RVFV infections (34). 
In mice infected with recombinant ΔNSs RVFV expressing luciferase, showed that 
luminescence signal in reproductive tissues, including the ovaries and uterus in female mice, was 
similar to levels seen in the spleen and liver, tissues of high tropism for RVFV infections (35). 
While mouse models are valuable for their ability to be manipulated and for studying 
differences between lethal and subclinical RVFV infection, the use of wildtype strains causes such 
rapid disease progression that long term immune response studies are difficult, which is a major 
limitation. 
1.3.2  Rats and the Rat Congenital Model 
Disease manifestations in rats infected with RVFV are dependent on rat strain, dose, and 
exposure route (36). Wistar-Furth rats succumb to hepatic disease and viremia within days of 
either subcutaneous or aerosol infection with RVFV (37). Lewis rats do not develop disease after 
subcutaneous exposure but become viremic. However, by the end of infection there is no detectable 
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viremia or virus in other common RVFV target tissues (37). In addition to these models, the 
Hartman lab has developed both a reproducible immunocompetent rat model of encephalitic 
disease in Lewis rats, and a congenital model of RVFV vertical transmission in pregnant Sprague-
Dawley rats (10, 38). 
McMillen et al. 2018 developed the first reproducible rodent model of congenital Rift 
Valley fever virus in Sprague-Dawley rats. Pregnant rats subcutaneously infected with ZH501 
strain RVFV exhibited vertical transmission and intrauterine fetal demise similar to what has been 
seen in livestock “abortion storms” during natural outbreaks. Vertical transmission occurred 
regardless of disease outcome in the dams. Sublethal dams gave birth to still-born pups with gross 
pathological changes and stunted development (10). Interestingly, despite RVFV generally 
displaying a hepatic tropism, viral titers were higher in the placenta than in the livers of these 
infected rats (10). Rat placentas have significant morphological and structural differences from the 
human placenta, but they are similar enough that rats are common in research on placental 
development and vaccine teratogenicity during pregnancy (39). This model of disease is 
understudied and interactions between pathogens and hosts during pregnancy remain poorly 
defined, particularly in the case of Rift Valley fever virus congenital disease. Studying the effects 
of RVFV infection in reproductive and fetal tissues is crucial to the continuing development of 
non-teratogenic vaccines and therapeutics.  
1.3.3  Non-Human Primates 
NHPs have long been used in RVFV studies, particularly in studies on the innate antiviral 
IFN response. Rhesus macaques are the most used non-human primate (NHP) model in RVF 
studies, with lethal to severe disease being seen in 20% of infections. Rhesus macaque studies have 
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been used to define pathogenesis of RVFV infection, investigate the dynamics of IFN responses 
and viral IFN antagonistic proteins, and for a number of vaccine studies (40-44). In a rhesus 
macaque model, IFN-α administration initiated 24 hours before or 6 hours post-infection was 
effective in protecting infected rhesus macaques from viremia, hepatocellular damage, and death 
(45). 
Across infection routes (aerosol, subcutaneous, intravenous) RVFV infection in rhesus 
macaques results in non-lethal fever, viremia, and in rare cases lethal hemorrhagic disease. 
Hartman et al. 2014 characterized RVFV aerosol infection in NHP models using three additional 
species: cynomolgus macaques, African green monkeys, and marmosets to evaluate them for their 
potential in developing an encephalitic model more similar to human disease progression (14). 
Cynomolgus macaques developed fever similar to rhesus macaques but did not develop 
encephalitis (14). Marmosets succumbed to severe neurological disease in low dose aerosol 
exposures, and encephalitic disease at high dose aerosol exposures. African green monkeys 
succumbed to similar neurologic disease after aerosol exposure but did not progress to symptoms 
or disease when exposed to RVFV subcutaneously (14).  
1.4 Rift Valley Fever Virus and Interferons 
1.4.1  Type I Interferons 
Interferons constitute the first line of immunological defense against viral infections. They 
are broken down into three classes: type I, II, and III IFNs. Each of these types of IFN function by 
activating intracellular antimicrobial responses through changes in gene expression and 
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subsequent protein production. Type I IFNs, IFN-α and IFN-β, are the first innate immunological 
response to viral infection, signaling through the receptor IFNAR which is expressed on all 
nucleated cells (46). Secretion of type I IFN in response to immune recognition of pathogen and 
damage-associated molecular patterns occurs through a well-defined system that was first 
described over 50 years ago (47).  Type I IFNs are the cytokines most predominantly produced in 
response to immunological pattern recognition receptor (PRR) binding to microbial peptides (48). 
The initial round of IFN-α/β signaling is currently understood to be induced through IRF3 and NF-
κB stimulation. Subsequent rounds of IFN signaling and induction are mainly the result of type I 
IFN endocytosis by IFNAR, followed by a signal cascade and the phosphorylation of STAT1 and 
STAT2, leading to altered gene expression and upregulated IFN production (49). Thus, type I IFNs 
can signal in a positive feedback loop where pro-inflammatory signaling feeds into itself further 
stimulating the immune response. Type I IFNs are potent proinflammatory interferons capable of 
inducing widespread antiviral immunity. Type I IFNs contribute to a general antiviral state through 
a variety of inducible changes including upregulated expression of MHC class I molecules and 
antigen presentation on all cells, activation of macrophages and dendritic cells, activation of 
Natural Killer (NK) cells, recruitment and activation of lymphocytes and enhanced effector 
function in CD4+ and CD8+ T cells (50-52). Type I IFNs also contribute to antiviral immunity 
through protein kinase R (PKR) which inhibits protein translation and synthesis through 
phosphorylation of eIF-2 protein synthesis initiation factor (46, 53). Type I IFN production and 
signaling results in a positive feedback loop of increasing type I IFN gene expression and protein 
release in an autocrine, paracrine, and endocrine manner. IFN-α/β have also been shown to induce 
over 300 interferon-stimulated genes (ISGs), 51 of which had host response specific functions, 
contributing to inflammation, immunomodulation and changes in host cell transcription to create 
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a more hostile microenvironment for the invading pathogen (54). These IFNs are the quintessential 
antiviral innate signaling molecules and play an indispensable role in the very early stages of 
infection.  
1.4.2  Type II Interferons 
Type II IFNs also play an important role in viral infections and are predominantly secreted 
by NK cells (55). In surrounding cells, NK secretion of type II IFN, IFN-γ, and subsequent binding 
to its receptor IFNGR, resulted in increased reactive oxygen species production particularly with 
nitric oxide (NO) production which is a potent inhibitor of viral replication (56). IFN-γ also 
stimulated phagocytotic function in macrophages as well as gearing immune cells, including NK 
cells, macrophages, and T cells to skew them towards a more proinflammatory profile (57). IFN-
γ plays a heavier role in dedicated myeloid and lymphoid immune cell signaling than it does in 
epithelial barrier cells where viral infection first occurs and functions more-so to coordinate the 
immune response after infection than controlling the very early stages of viral infections as type I 
IFNs do.  
1.4.3  Type III IFNs  
Type III interferons, the IFN-λ family of proteins, are a recently characterized group of 
innate antiviral molecules that function in modulating host immune responses to viral infection at 
epithelial barriers, including at the placenta. Unlike type I interferons which elicit antiviral 
responses in all nucleated cells, expressing the IFNAR1 receptor, type III interferons elicit a more 
localized innate antiviral response, with the heterodimeric receptor for IFN-λ proteins, 
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IL28Rα/IL10Rβ, only found on barrier epithelial cells (58). The type III interferon family includes 
IFN-λ1, IFN-λ2, IFN-λ3, and IFN-λ4 in humans; with IFN-λ1-3 proteins exhibiting localized pro-
inflammatory and antiviral functions, and IFN-λ4 demonstrating immunoregulatory function in 
attenuating the antiviral response (59). Interestingly, type III IFNs have been demonstrated to be 
induced by type I IFN stimulation, making IFN-λs an ISG of type I IFNs (60). In mice, only IFN-
λ2/3 are functional (61).  
1.4.4  The role of IFNs in Congenital Viral Infection 
Type I IFNs contribute extensively to the immune environment during pregnancy and are 
necessary for protection of the pregnancy through their antiviral properties (62). Type I IFN 
dysregulation can also contribute to immunopathology during pregnancy (62). Elevated levels of 
type I IFN are associated with antiphospholipid syndrome events and earlier onset for preeclampsia 
in human pregnancies (63). Additionally, type I IFN responses induced by viral infection during 
pregnancy can block fusion of the syncytiotrophoblast layer of cells in the placenta, which is 
necessary for viral defense, and can contribute to immunopathology and loss of barrier integrity at 
the placenta (64). Zika virus (ZIKV), a flavivirus with similar transmission dynamics to RVFV 
including vertical transmission, has been implicated in this phenomenon. In a mouse model of 
ZIKV vertical transmission, researchers found that only infected mice with competent IFNAR1 
receptors exhibited resorption of the fetus after ZIKV infection. IFNAR signaling as a result of 
ZIKV infection inhibited placental labyrinth development resulting in abnormal architecture of the 
maternal-fetal environment and further work in human chorionic villous explants suggested that 
type I IFNs, but not type III IFNs, altered placental morphology implicating type I IFNs as potential 
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mediators of adverse pregnancy complications, including spontaneous abortion in the context of 
viral infections (65).   
Previous work has examined a type III interferon, IFN-λ1, and its ability to confer 
protection at the placental barrier during Zika virus (ZIKV) infection (66). ZIKV is an emerging 
flavivirus and the latest in a group of pathogens known as TORCH pathogens (Toxoplasma gondii, 
other, rubella virus, cytomegalovirus and herpes simplex virus) which cause congenital infections 
and can gain access to the fetal compartment in infections during pregnancy. IFN-λ administration 
during pregnancy reduced ZIKV burden in maternal and fetal tissues and reduced placental injury 
and fetal demise (67). Further, gestational stage has been shown to impact ZIKV pathogenesis, 
with IFN-λ mediated immunity at the maternal-fetal interface. This phenomenon may be due to 
changes in IFN-λ signaling throughout gestational stage or possibly changes in expression of 
potential entry receptors for the virus (66, 68). Mouse models lacking IFN-λ receptors had 
increased ZIKV replication in the placenta and fetus, while IFN-λ treatment reduced ZIKV 
infection in pregnant mice (69). Primary human trophoblasts, the barrier cells of the placenta, 
constitutively release IFN-λs which protects trophoblast and non-trophoblast cells from Zika virus 
infection, suggesting the virus must use alternative pathways to cross the placental barrier (66, 70).  
Human Cytomegalovirus (HCMV), another congenital viral infection, is a significant cause 
of congenital morbidity and mortality with roughly 5 out of every 1,000 infants born every year 
infected, 10% of whom will experience neurological disease (71). IFN downregulation by HCMV 
is well-documented (72). To date, work done to characterize the relationship between type III IFNs 
and HCMV has focused on IFN-λ signaling during CMV infection post-organ transplant and with 
HIV co-infection, immunocompromised at-risk populations for CMV infection and reactivation. 
In this field, IFN-λ has been shown to be a potent antiviral ISG activator, and IFN-λ induced 
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signaling resulted in significant reduction of cells positive for CMV immediate-early protein (73, 
74). However, in the case of HIV-coinfected individuals, IFN-λ genotype did not have an effect 
on susceptibility to CMV reactivation (75). To date, no work has been published characterizing 
congenital CMV infection and its relationship to IFN-λs. 
Herpesviruses also have congenital properties when infections occur during pregnancy. 
Both HSV-1 and HSV-2 have been shown to be sensitive to the antiviral properties of IFN-λs, 
where signaling has resulted in reduced viral titers, however these effects were cell type dependent. 
IFN-λ treatment was effective in reducing titers in the case of hepatic and neuronal cell infection 
(60, 76). Additionally, type III IFNs are capable of and necessary in inducing NF-κB, ICP27, and 
IRF-3 in HSV-1 infections (77). To date, no work has been published on HSV congenital infection 
and its relationship to type III IFNs.  
1.4.5  Rift Valley fever virus and type I IFNs 
In RVFV infection, IFN-α has been shown to be capable of preventing clinical disease in 
RVFV infected rhesus macaques and can suppress RVFV viremia (45). However, RVFV non-
structural protein NSs has also been demonstrated to block type I IFN production by targeting the 
transcription factor TFIIH (78). NSs inhibits IFN-β production by interacting with the transcription 
factor YY1 that regulates IFN-β gene expression through a SAP30 complex which acts as a 
repressor on the IFN-β promoter (79). The presence of NSs in infected cell nuclei also induces 
DNA damage responses and causes cell cycle arrest and apoptosis. NSs also promotes the 
degradation of TFIIH p62 and PKR proteins (80).  
While an extensive body of research has been done investigating the relationship between 
Rift Valley fever virus and IFN-α/β, thus far no work has been done to investigate interactions 
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between type III IFNs and RVFV. This work addresses that gap in the field by determining the 
effect of type III IFNs on RVFV with a direct comparison to type I IFNs.  
1.5 Placenta Structure and Function 
1.5.1  Placenta Structure 
The human placenta is organized in a villous structure, resembling branches of a tree, to 
maximize surface area for the exchange of nutrients in the intervillous space and the maternal-fetal 
interface (81). Syncytiotrophoblasts form the outermost cell layer of the placenta and this layer is 
a long, continuous multinucleated unit of cytoplasm. Directly beneath this layer are the 
cytotrophoblasts which function in anchoring the developing fetus and placenta to the uterine wall. 
Cytotrophoblasts expand and proliferate into the maternal decidua where they are termed 
extravillous trophoblasts (EVTs). EVTs may represent a potential entry point in for other TORCH 
pathogens like Zika and CMV, as well as the possibility that these infections are mediated by 
trafficking of infected maternal immune cells across the placenta, through breaks in the 
syncitiotrophoblast layer, or through ascending infection (81). In the case of RVFV vertical 
transmission, RVFV has been shown to directly infect syncytiotrophoblasts, a phenomenon unique 
to RVFV (10).   
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1.5.2  Function of the Placenta as an Immune Barrier 
The placenta represents the physical barrier layer between the maternal blood supply and 
the developing fetus. Of importance are placental syncytiotrophoblasts which develop into a 
complete layer enveloping the implanted embryo by day 7 post-fertilization and are largely 
responsible for nutrient and waste exchange in the maternal-fetal interface (82). Once the 
uteroplacental circulatory system is established at about 12 weeks of gestation, these fetal-origin 
syncytiotrophoblasts are the only cells that come into direct contact with maternal blood (83, 84). 
This makes this cell layer indispensable in microbial defense and these cells are traditionally 
considered to be entirely microbially resistant. The source of this resistance is due largely to their 
morphological novelty, lacking intercellular junctions and receptors, as well as the elasticity 
conferred by having one multi-nucleated cytoplasm (85). In addition to these properties, 
syncytiotrophoblasts constitutively secrete type III IFNs, establishing an immune 
microenvironment at the placental barrier that primes trophoblasts in a paracrine and autocrine 
fashion for resistance to microbial infection (86). Little is known about specific mechanisms by 
which viruses capable of congenital infection breach or bypass the placental barrier to access the 
developing fetus. This work represents the first characterization of how RVFV may circumvent 
the type III IFN-mediated immune response in this critical syncytiotrophoblast layer.  
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2.0 Statement of Project and Specific Aims 
Rift Valley fever virus (RVFV) is an emerging virus of domesticated livestock endemic to 
many regions of Africa that is spread by multiple mosquito species (1). RVFV outbreaks 
commonly affect sheep and cattle, resulting in a wide range of clinical manifestations including 
hepatic and neurological disease. Human clinical manifestations have included hepatic disease and 
hemorrhagic fever as well as encephalitic disease. One of the most devastating characteristics seen 
in previous outbreaks is the phenomenon of widespread spontaneous virally-induced abortion 
among pregnant livestock (6). An association has also recently been demonstrated between women 
who are infected with the virus and increased likelihood of late term miscarriage (8). RVFV 
infection in pregnant women may carry the potential for vertical transmission to the child. There 
are a few documented cases of vertical transmission in naturally occurring outbreaks (9). Vertical 
transmission has also been demonstrated in recent laboratory experiments using a rat model in the 
Hartman lab (10). Pregnant rats were inoculated with wildtype RVFV subcutaneously, mimicking 
the mosquito bite transmission seen in natural infections. Pregnant rats more susceptible to death 
as compared to their nonpregnant counterparts. In addition, reproductive tissues were shown to be 
targets of RVFV infection including the placenta, uterus, ovary, and amniotic sac and direct 
vertical transmission of the virus to pups during late gestational stage resulted in pup deformity 
and death.  
All these data and findings taken together indicate that RVFV may have significant 
potential for vertical transmission and serious adverse consequences in pregnant women. What the 
above evidence lacks is a clear understanding of how RVFV accomplishes such a prolific and 
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detrimental infection in the maternal-fetal environment. The work performed here represents a 
start at understanding this critical phenomenon by examining the effect of type III IFNs on RVFV.   
IFNs are the main arm of innate antiviral immunity. They function in the earliest host 
response to infection. IFN responses utilize autocrine and paracrine signaling to induce a hostile 
microenvironment for the invading pathogen, alter host-cell transcription to induce an antiviral 
state, and function in activating and recruiting immune cells to sites of infection. IFNs are 
separated into three types: I, II, and III.  
The relationship between RVFV and IFNs is complex. RVFV nonstructural protein NSs 
has been previously demonstrated to downregulate type I IFN (IFN-β) expression in infected cells 
(45, 87). Conversely, IFN-α treatment has been shown to be effective in preventing or greatly 
suppressing viremia (58).  
Type III interferons, the IFN-λ family of proteins, are a recently characterized group of 
innate antiviral molecules that function in modulating host immune responses to viral infection at 
epithelial barriers, including at the placenta. To date, no work has been performed to study the 
possible effects of type III IFNs on RVFV infection or pathogenesis in any context, let alone 
pregnancy and vertical transmission.  
We will address this gap in the field by examining the relationship between RVFV and 
IFN-λ in vitro, using relevant epithelial cell lines. Placental tissues from livestock, rodents and 
humans have been demonstrated to be particularly permissive to RVFV infection (10, 88). 
Therefore, we hypothesize that RVFV may be resistant to the effects of type III IFNs at epithelial 
cell barriers such as the placenta, contributing to the frequency of vertical transmission of the virus. 
We further hypothesize that resistance of RVFV to type III IFNs is due to the action of NSs, a 
nonstructural protein that is known to inhibit other interferon type pathways (23,24). The 
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sensitivity of RVFV to type III interferons will be determined, and we will also determine the 
mechanisms by which RVFV may avoid or downregulate type III IFN responses during infection. 
In these studies, we hope to gain more information on how RVFV avoids the specific barrier-layer 
immune defense of IFN-λ at the placenta. We will address our hypothesis using the following 
specific aims: 
AIM 1: Determine RVFV sensitivity to exogenous IFN-λ1. Type I IFNs (i.e. IFN-β) can 
inhibit infection and replication of RVFV despite the fact that the viral NSs protein acts as an 
interferon antagonist. It is currently not known whether RVFV is sensitive to type III IFNs. To 
address the ability of type III IFNs to inhibit RVFV infection, the permissivity of relevant cell 
lines to RVFV infection will be determined in the presence or absence of the addition of IFN-λ or 
IFN-β (as a control) at different times before or after infection.  
AIM 2: Determine the role of RVFV non-structural protein NSs in modulating 
expression of IFN-λ1 stimulated genes (ISGs). We will determine whether the viral NSs protein 
can inhibit ISG promoter activation and gene expression after stimulation of cells with either IFN-
λ or IFN-β. Three ISGs of interest were selected: PKR, CXCL3, and CXCL8.  
AIM 3: Determine the role of RVFV non-structural protein NSs in modulating IFN-
λ1 expression. The goal of this aim is to determine whether NSs can prevent the induction of IFN-
λ protein expression after treatment of relevant cell lines with a potent IFN inducer polyI:C. 
Presence of interferons in cell culture supernatant will be measured by ELISA for differing doses 
of NSs and poly (I:C) concentrations. 
At the conclusion of this study, we will have characterized the sensitivity of RVFV to IFN-
λ1 at epithelial cell barriers and compared that to IFN-β, in which the effects of RVFV are more 
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well characterized. In addition, we hope to describe the effect of NSs protein on IFN-λ stimulated 
gene expression, and on expression of IFN-λ protein in epithelial cells. 
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3.0 Materials and Methods 
3.1 Biosafety 
All work with RVFV was performed in the biosafety level 3+ Regional Biocontainment 
Laboratory (RBL) at the University of Pittsburgh Center for Vaccine Research. Personnel wore 
powered air-purifying respirators (PAPRs), waterproof apron, and facility designed shoes. The 
RBL is a shower-out facility that requires a full clothing change into scrubs before entry and a 
personal shower and change into new scrubs to exit. Work was conducted in a class III biosafety 
cabinet (BSC) using Vesphene IIse (Steris Corporation, cat. #646101) at a 1:128 working dilution 
as a disinfectant. All samples removed from the BSL-3 were inactivated using methods described 
below which have been verified and approved by a University of Pittsburgh biosafety oversight 
committee.  
3.2 Viruses and Cells 
The ZH501 strain of RVFV was provided by Barry Miller (CDC, Fort Collins, CO) and 
Stuart Nichol (CDC, Atlanta, GA). The recombinant GFP-RVFV virus, containing a deletion for 
the NSs gene, was obtained courtesy of Jeroen Kortekaas (Wageningen University, Wageningen, 
Netherlands). Virus was propagated on VeroE6 (CRL-1586, ATCC) cells in standard culture 
conditions using Dulbecco’s modified Eagle’s medium (DMEM) containing 2% (D2) or 10% 
(D10) fetal bovine serum (FBS), 1% penicillin-streptomycin (pen/strep), and 1% L-glutamine.  
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Two immortalized cell lines HepG2 (HB-8065, ATCC) and BeWo (CCL-98, ATCC) cells, 
were used to model hepatocyte and placental trophoblast cell types, respectively. HepG2 cells are 
an immortalized hepatocellular carcinoma cell line chosen to mimic the hepatic tropism of RVF 
disease. BeWo cells are a choriocarcinoma cell line chosen for their ability to form syncytia and 
for closely mimicking placental syncitiotrophoblasts previously described as a unique cell type 
infected by RVFV. HepG2 cells were maintained in standard culture conditions using D10 or D2. 
BeWo cells were maintained in standard cell culture conditions using Kaighn’s Modification of 
Ham’s F12 medium (F-12K) with 20% FBS during growth or 2% FBS during infection (30-2004, 
ATCC).  
3.3 Viral Plaque Assay 
To determine viral titers via plaque assay, VeroE6 cells were seeded in a 6-well plate with 
D10 media at high density one day before to ensure confluency on the day of the assay. The 
following day the virus to be titered was serially diluted in D2 media at 1:10 dilutions, from 10-1 
to 10-6. For each dilution, 200 ul were added to each well in duplicate and each 6-well plate was 
incubated at 37 C, 5% CO2 for 1 hour, rocking every 15 minutes. After an hour, the inoculum was 
removed and replaced with 3 ml of a 1:1 mixture of nutrient media and agar. Once the mixture 
solidified to create a gel plug, plates were placed back in the 37 C incubator for 3 days. After 3 
days, 2 ml of 37% formaldehyde was added to each well and left overnight to inactivate virus and 
fix the wells. The following day, formaldehyde and gels were disposed of as chemical waste. The 
cells were then rinsed with distilled water and stained with 0.1% crystal violet (CV) working 
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solution for 10 minutes. After CV solution was rinsed off, the resulting plaques were counted from 
each duplicate, averaged, and used to calculate viral titer.  
3.4 Quantitative Real-Time Reverse Transcriptase PCR 
Infectious materials to be analyzed by PCR were first inactivated using an approved 
protocol by the University of Pittsburgh RBL Biosafety Officer. To do this, 100 ul of infectious 
sample was added to 900 ul of TRIzol reagent (Invitrogen, cat. #15596026) in a 1.7 mL Eppendorf 
tube, capped and vortexed. The tube was kept capped and allowed 10 minutes of contact time at 
room temperature for full inactivation. Samples were then transferred to a new Eppendorf tube, 
removed from the BSL-3 to BSL-2 lab space, and stored at -80 C until ready for RNA extraction.  
RNA extraction was performed using a modified version of the PureLink RNA Mini Kits 
protocol (Invitrogen, cat. #12183018A). Final samples were run on a 96-well plate in duplicate 
against a known standard curve and quantified based on the standard curve generated on each 
plate. PCR results were reported in relative PFU/ml equivalence based on prior calculations 
comparing standard curves to plaque assay results. 
3.5 PKR, CXCL3, and CXCL8 Quantitative Real-Time PCR 
Samples to be analyzed for interferon stimulated gene (ISG) expression came from isolated 
RNA as previously described. RNA samples underwent cDNA synthesis to generate 1X stocks of 
cDNA for qPCR. PCR analysis was conducted in multiplex using AB TaqMan  Multiplex Master 
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Mix 2X (Applied Biosystems, cat. #4484263), and a primer probe specific for each ISG: PKR 
(ThermoFisher Scientific, assay ID: Hs00169345_m1 (FAM)); CXCL3 (ThermoFisher Scientific, 
assay ID: Hs00174103_m1 (FAM)); and CXCL8 (ThermoFisher Scientific, assay ID: 
Hs00174103_m1 (FAM)) normalized to an endogenous β-actin control (ThermoFisher Scientific, 
assay ID: Hs01060665_g1 (VIC)). mRNA expression levels were calculated using the ΔΔCT 
method and expressed as fold-change compared to untreated controls. 
3.6 Lipofectamine Transfection 
To analyze potentials effects of RVFV protein NSs on IFN protein production, cells were 
plated to 70-90% confluency in Opti-MEM reduced serum medium (ThermoFisher, cat. 
#31985062) and incubated overnight at 37 C, 5% CO2. Transfections were performed using 
Lipofectamine 3000 Transfection Reagent (ThermoFisher Scientific, cat. #L3000001) following 
manufacturer instructions. Cells were transfected with either an NSs-GFP expression plasmid or 
an empty backbone control and transfection efficiency was verified by fluorescence microscopy. 
The following day, transfection media was replaced with fresh growth media with 2% FBS. Wells 
were then treated with poly(I:C) dsRNA mimic (R&D Systems, cat. #4287/10) at a range of 
concentrations and supernatants were collected at 4, 12, and 24 hours post-stimulation.  
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3.7 Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISAs to detect presence of secreted IFN proteins were performed on samples of interest 
using Human IL-29/IL-28B (IFN-λ1/3) DuoSet ELISA kits (R&D Systems, cat. #DY1598B-05), 
Human IFN-β DuoSet ELISA kits (R&D Systems, cat. #DY814-05) along with DuoSet ELISA 
Ancillary Reagent Kit 2 (R&D Systems, cat. #DY008). Supernatants were analyzed in duplicate 
in 96-well plates and compared to a known standard for each plate per manufacturer’s instructions. 
Results were reported in pg/ml. 
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4.0 Results 
4.1 AIM 1: Determine RVFV sensitivity to exogenous IFN-λ1. 
HepG2 and BeWo cells were the cell lines chosen for these experiments. HepG2 cells are 
a hepatocellular carcinoma epithelial cell line used in IFN-λ research, particularly in the field of 
hepatitis (89). Their ability to secrete and respond to type III IFNs has been well-documented in 
the literature (90). Due to this and their extensive use in hepatitis virology, they were chosen as an 
appropriate cell line to mimic the hepatic form of RVF disease. BeWo cells are a choriocarcinoma 
cell line widely used to model placenta trophoblast cells in vitro (91). BeWo cells are an 
immortalized trophoblast cell line and have been used in viral research, importantly being 
demonstrated to form syncytia, which set these cells apart from other common placental cell lines 
(92). Due to their trophoblast origin and record of viral research in the literature, BeWo cells were 
selected as the best placenta cell line to investigate RVFV infection in vitro. 
To determine the optimal timepoint to use for viral infections in HepG2 and BeWo cell 
lines, a time-course experiment was conducted. BeWo or HepG2 cells were plated on 6-well plates 
at a density of 1.5 x 105 cells/well. The following day, each cell line was infected at 0.01 MOI with 
the pathogenic, wildtype ZH501 strain of RVFV (wt RVFV). This MOI was chosen as a moderate 
MOI that would result in productive infection over a short timeframe but avoiding killing the cells 
too rapidly. Viral production in each cell line peaked at 48 hours-post-infection (hpi), and this 
timepoint was chosen as the point of analysis for subsequent experiments (Figure 2). 
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Figure 2: ZH501 RVFV viral titers over time in HepG2 and BeWo cells.  
Mean viral titers in cell supernatants by qRT-PCR for HepG2 and BEWo cells infected at 0.01 MOI. (n=3, bars 
indicate SD)   
 
To assess whether RVFV is sensitive to exogenous type III IFN treatment, HepG2 and 
BeWo cells were plated at a density of 1.5 x105 cells/well on 6-well plates. The following day, 
cells were infected at 0.01 MOI wt RVFV and treated with increasing doses of exogenous IFN-λ1 
(0, 10, 100, or 1,000 ng/mL) at the time of infection (0 hours post-infection; hpi) or 24 hpi. These 
treatment times were chosen based off of in vivo RVFV infection data demonstrating that pre-
treatment or immediate post-infection treatment with IFN-α was effective in reducing viral titers 
in animals compared to delayed treatment (45). Cells were also infected similarly and treated with 
IFN-β at 0 or 24 hpi as a control based on previously published data, with the expectation that 
immediate treatment of cells with type I IFN would result in reduced viral titers. Supernatants and 
cell lysates were taken at 48 hpi and analyzed by viral plaque assay and qRT-PCR to determine 
viral titers (Figure 3).  
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Exogenous IFN-β and IFN-λ1 treatment inhibited RVFV production in HepG2 cells when 
cells were treated immediately after infection (0 hpi) with 10, 100, or 1,000 ng/ml, as compared to 
untreated controls; conversely, delayed treatment with either IFN at 24 hpi had no effect on virus 
production in HepG2 cells (Figure 3). We hypothesize, and will test later in this thesis, that the 
resistance of HepG2 cells to delayed IFN treatment may be due to the action of the RVFV IFN 
antagonist NSs protein. Notably, IFN-λ1 treatment did not diminish RVFV production in BeWo 
cells regardless of time of addition (Figure 3). This may help to explain the underlying mechanism 
of why RVFV replicates well in the placenta despite constitutive IFN-λ secretion under normal 
conditions (10, 66). These experiments indicate that RVFV is sensitive to and can be inhibited by 
type III IFNs, although this is cell-type dependent as treatment of BeWo cells did not affect RVFV 
viral production. 
As previously discussed, Rift Valley fever virus non-structural protein NSs is a known type 
I IFN antagonist (78). To assess whether NSs may be mediating RVFV resistance to the antiviral 
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Figure 3: The effect of IFN treatment on ZH501 RVFV viral titers in HepG2 and BeWo cells. 
Mean viral titers at 48 hpi measured by viral plaque assay (VPA) for HepG2 and BeWo cells infected at 0.01 MOI 
with ZH501 RVFV and treated with exogenous IFN-λ1 or IFN-β at 0 hpi (A, C) or 24 hpi (B, D). (n=3, bars indicate 
SD). Data are expressed as percentage of untreated controls from log-transformed viral titers. Asterisks indicate 
significance (*, P <0.05, ***, P < 0.001) by Two-Way ANOVA, Tukey’s multiple comparison test. NT = not tested. 
 
effects of type III IFNs, the same infection protocol was repeated with RVFV-ΔNSs/GFP,  
containing a deletion for the NSs protein and an insertion of eGFP in its place. HepG2 and BeWo 
cells were infected with RVFV-ΔNSs/GFP at 0.01 MOI and treated with IFN-λ1 or IFN-β at 0 and 
24 hpi, and virus production was measured by qRT-PCR at 72 hpi. This later time point was chosen 
to account for the slower growth kinetics of ΔNSs-RVFV.RVFV-ΔNSs/GFP infection of HepG2 
cells was dramatically inhibited by IFN-β but not IFN-λ1 regardless of time of treatment (Figure 
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4A). These resulted indicated that sensitivity of RVFV to IFN-β but not IFN-λ1 was enhanced in 
the absence of the NSs protein.   
Contrary to what we expected, RVFV-ΔNSs/GFP was not more sensitive to IFN-λ1 in 
BeWo cells when added at either treatment time (Figure 4), indicating that RVFV infection and 
antiviral resistance to type III IFNs in this trophoblast cell line may not be mediated by the action 
of NSs. RVFV-ΔNSs/GFP was also less sensitive to IFN-β in BeWo cells compared to wt RVFV, 
which was contrary to our hypothesis.  
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Figure 4: RVFV-ΔNSs/GFP viral titers at 72 hpi in HepG2 and BeWo cells. 
Mean viral titers by qRT-PCR for HepG2 and BeWo cells infected at 0.01 MOI and treated with exogenous IFN-λ1 
or IFN-β at 0 hpi (A) or 24 hpi (B). Data are expressed as percentage of untreated controls from log-transformed 
viral titers. Asterisks indicate significance (***, P < 0.001) by Two-way ANOVA, Tukey’s multiple comparison 
test. NT = not tested. 
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To confirm these results and expand the range of timepoints to analyze for effects of IFN-
λ1 treatment on RVFV infection in BeWo cells, a time course experiment was conducted. BeWo 
cells were plated as in Aim 1 and treated with 0, or 1,000 ng/mL of IFN-λ1 or IFN-β at 6 hours 
pre-infection, 0, 24, or 48 hours-post-infection. Cell supernatants were taken every 24 hours from 
0 to 72 hpi and analyzed by qRT-PCR to quantify viral titers (Figure 5).       
In support of data from Figure 3, IFN-λ1 treatment did not result in a significant reduction 
in viral titers with any treatment time. Conversely, IFN-β treatment 6-hour pre-infection and 0 hpi 
did reduce viral titers as compared to controls.  
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Figure 5: ZH501 viral titers at 0, 24, 48, and 72 hpi in BeWo cells. 
 34 
Mean viral titers by qRT-PCR in BeWo cells infected with 0.01 MOI ZH501 RVFV and treated at -6 (A), 0 (B), 24 
(C) or 48 (D) hpi, with 1,000 ng/mL IFN-λ1 or IFN-β, compared to an untreated control. Asterisks indicate 
significance (**, P < 0.01; ***, P < 0.001) by Two-way ANOVA, Tukey’s multiple comparison test. 
 
4.2 AIM 2: Determine the role of RVFV nonstructural protein NSs in inhibiting expression 
of IFN-λ1 stimulated genes (ISGs). 
Results from Aim 1 indicate that treatment of HepG2 cells with IFN-λ1 can limit the 
production of infectious RVFV virus. Interestingly, this was not the case with the trophoblast cell 
line BeWo, and the resistance of BeWo cells could be only partially attributed to the presence of 
NSs. In Aim 2, we seek to specifically determine the effect of the viral NSs protein on activation 
of ISG promoter and several ISGs in response to IFN-λ1 treatment.  
In order to determine whether the viral NSs protein can affect ISG promoter activation and 
gene expression after stimulation with either IFN-λ1 or IFN-β, HEK-293T cells were transfected 
with a luciferase reporter plasmid under the control of an interferon-stimulated response element 
(ISRE) promoter along with an NSs expression plasmid or an empty vector control. Transfected 
cells were treated with IFN-λ1 or IFN-β, and 24 hours after IFN treatment, ISRE activation was 
quantified by dual luciferase assay.  
The ISRE promoter was activated in a dose-dependent manner by treatment with either 
IFN-λ1 or IFN-β. This activation was inhibited by co-transfection with NSs (Figure 6). These 
results indicate that NSs can prevent activation of the ISRE promoter after both IFN-λ1 and IFN-
β treatment, suggesting that in theory NSs can mediate resistance to IFN-λ treatment similarly to 
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IFN-β. However, clearly other factors are at play given that RVFV titers were unaffected by IFN-
λ treatment in BeWo but not HepG2 cells. 
Knowing that NSs can function to inhibit IFN-λ mediated ISRE activation despite the 
observation that there was a discrepancy in titer reduction between BeWo and HepG2 cells, we 
next measured ISG expression in cell lysates from the infection experiments described in Aim 1. 
We measured three ISGs that have a known or suspected role in the pathogenesis of RVFV: protein 
kinase R (PKR), CXCL3(also known as GRO3 and MIP2B), and CXCL8 (also known as IL-8). 
PKR functions early in the antiviral response pathway, primarily by inhibiting protein synthesis 
(53). PKR inhibits viral protein synthesis by targeted protein ubiquitination and proteosomal 
degradation through E3 ligases. RVFV NSs protein is known to degrade protein kinase R, an early 
E3 ligase in the IFN-response pathway, as well as promoting post-transcriptional downregulation 
and inhibiting necessary phosphorylation for PKR to function (87, 93). CXCL3 is the cytokine 
ligand of CXCR2 (also a receptor for CXCL8) and mainly functions as a chemoattractant  
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Figure 6: NSs inhibits ISRE activation in response to IFN-λ1 and IFN-β treatment. 
ISRE-luciferase expression in HEK-293T cells transfected with NSs expression plasmid at 24 hours post-treatment 
with IFN-λ1 or IFN-β. Luciferase expression displayed in percent change (%) normalized to constituitively 
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expressed renilla plasmid luminescence. Cells were transfected with 1 ug/well each of NSs expression plasmid or 
empty backbone control plasmid, ISRE-luciferase reporter plasmid, and renilla expression plasmid. (n=3, bars 
indicate SD) Asterisks indicate significance compared to untreated controls (*, P < 0.05) by Two-way ANOVA, 
Tukey’s multiple comparison test. 
 
controlling the migration and adhesion of monocytes and neutrophils in sites of infection, 
particularly the cerebellum (94). Recent work on neutrophil and macrophage influx during 
encephalitic RVFV infection has highlighted the inflammatory components of lethal RVFV in a 
rodent model (95). Additionally, immunostaining has shown localization of CXCL3 in 
trophoblasts of human placenta explants (96). CXCL3 has also been shown to play a role in the 
migration, invasion, and proliferation of placental trophoblast cells (97).  CXCL8, also known as 
IL-8, is a chemokine produced by macrophages, epithelial cells, and airway smooth muscle cells. 
It is a proinflammatory chemokine that attracts macrophages and neutrophils as well as stimulating 
phagocytosis. In RVFV infections in mice, increases in CXCL8 signaling are associated with 
pathogenesis in the brain and liver (98). In rats, high levels of the IL-8 homolog GRO/KC were 
associated with lethal infection (38). Similarly in NHPs, higher IL-8 levels late in infection, along 
with other proinflammatory markers, were found in animals with severe disease, however early 
expression of those same markers was seen in survivors (99). In human cases, elevated CXCL8 
level in serum are indicative of more sever disease (100).  
In IFN-β treated HepG2 and BeWo cells, expression of each of these ISGs was 
downregulated in ZH501 RVFV infection compared to uninfected IFN treated cells, regardless of 
whether those cells were treated at 0 or 24 hpi. In IFN-λ1 treated HepG2 cells, PKR and CXCL8 
expression was downregulated in ZH501 infected cells compared to uninfected controls. In BeWo 
cells however, IFN-λ1 treatment was only significantly downregulated in ZH501 infected cells for 
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CXCL3. BeWo cell ISG expression was relatively unresponsive overall, even in uninfected cells, 
in response to IFN-λ1 treatment.  
Overall, these data indicate that the NSs protein is not necessary in RVFV inhibition of 
IFN-λ1 stimulated genes for both HepG2 and BeWo cells; but, RVFV-ΔNSs/GFP is unable to 
inhibit IFN-β stimulation of CXCL3 and CXCL8 in BeWo cells.  
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Figure 7: RVFV infection inhibits PKR mRNA expression in HepG2 and BeWo cells, independent of the 
presence of NSs. 
Mean mRNA expression levels by qPCR for 0.01 MOI infected HepG2 (A, B) and BeWo (C, D) cells treated with 
IFN-λ1 at 0 or 24 hpi. Expression of each ISG normalized to an endogenous β-actin control. 
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Figure 8: RVF infection inhibits CXCL3 mRNA expression in HepG2 cells independent of the presence of 
NSs, but requires NSs to inhibit expression in IFN-β treated BeWo cells. 
Mean mRNA expression levels by qPCR for ZH501 0.01 MOI infected HepG2 (A, B) and BeWo (C, D) cells 
treated with IFN-β at 0 or 24 hpi. Expression of each ISG normalized to an endogenous β-actin control. 
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Figure 9: RVFV infection inhibits CXCL8 mRNA expression in HepG2 cells, independent of NSs, but requires 
NSs to inhibit expression in IFN-β treated  BeWo cells.  
Mean mRNA expression levels by qPCR for ZH501 0.01 MOI infected HepG2 (A, B) and BeWo (C, D) cells 
treated with IFN-β at 0 or 24 hpi. Expression of each ISG normalized to an endogenous β-actin control. 
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4.3 AIM 3: Determine the role of RVFV non-structural protein NSs in reducing IFN-λ1 
protein production. 
Aim 2 determined that NSs can inhibit IFN-λ1-mediated ISG production under certain 
circumstances. Aim 3 is designed to determine whether NSs can inhibit the induction of IFN-λ 
protein after treatment of cells with the potent IFN-inducer poly(I:C). Poly(I:C) is a dsRNA mimic 
used to induce TLR3 signaling and subsequent IFN-λ1 or IFN-β protein production (90). IFN 
production from NSs transfected cells was measured at 0, 4, 12, and 24 hours post-poly(I:C)-
stimulation and compared to cells transfected with an empty backbone control. Presence of IFNs 
in cell supernatant was measured by enzyme-linked immunosorbent assay (ELISA). HepG2 or 
BeWo cells were plated in 24-well plates and transfected with 0, 0.5, 1, or 2 ug NSs expression 
plasmid as in Aim 2. 24 hours post-transfection, cells were treated exogenously with 0, 5, 10, or 
15 ug/mL of poly(I:C) dsRNA mimic to induce TLR3 stimulation and subsequent IFN protein 
production. Supernatants were taken at 4, 12, and 24 hours post-stimulation and analyzed by 
ELISA for the presence of IFN-λ or IFN-β (Figure 10).  
In BeWo cells, both IFN-β and IFN-λ protein production was below the limit of detection 
under all treatment conditions. In HepG2 cells, IFN-β production was below the limit of detection 
(data not shown). In contrast, IFN-λ production was detectable, but protein levels in cell 
supernatants were not reduced in cells transfected with NSs expression plasmid, indicating that 
while NSs may have an effect on IFN-stimulated genes, it does not appear to have an effect on 
IFN-λ protein secretion in HepG2 cells (Figure 10). 
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Figure 10: NSs transfection has no effect on IFN-λ protein production in HepG2 cells in response to poly (I:C) 
stimulation at 4, 12, and 24 hours post-stimulation. 
IFN-λ protein levels measured by ELISA, calculated based on a standard curve of known concentrations of IFN-λ in 
pg/mL.   
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5.0 Discussion 
Since its discovery in 1931, RVFV has caused outbreaks throughout Africa, the Saudi 
Peninsula, and Madagascar. Mosquito-facilitated RVFV spread has resulted in the establishment 
of endemic RVFV in Africa where frequent enzootic and epizootic transmission has been 
documented. In livestock, RVF primarily presents as a fulminant hepatic disease, which can occur 
in a variety of domestic ruminants (101-104). Vertical transmission and mass-abortogenic 
infections in livestock has been a consistent phenomenon in enzootic outbreaks. 
In humans, the most common form of RVF disease is a self-limiting febrile illness, 
however more serious clinical manifestations can occur (20). In a large case study of individuals 
with laboratory confirmed cases of RVF during the Saudi Arabian outbreak in 2000, 93% of cases 
presented with fever, followed by 17% with neurological disease, and 7% including hemorrhagic 
manifestations (18). Despite well-documented epidemiological and clinical data from a myriad of 
human outbreaks, confirmed cases of human vertical transmission are limited to only two cases. 
Two pregnant women gave birth to an infant with jaundice, and an enlarged spleen and liver, and 
a serologically positive infant that later succumbed to infection (9, 105). More broadly, a cross-
sectional study of pregnant women with concomitant RVFV infection established an association 
between infection and late-term miscarriage in 54% of the women with an odds ratio of 7.4 (8). 
Despite the lack of data on this phenomenon in humans, abortion storms in livestock infected with 
RVFV are a hallmark of zoonotic outbreaks and highlight the ability of the virus to cause 
congenital infection. Laboratory work exploring RVFV vertical transmission has been 
understudied. To this end, McMillen et al. (2018) developed a rodent model for congenital RVFV 
infection. This model has the benefit of the rat and human placenta structures sharing key 
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characteristics, both being hemochorial and discoid-shaped (106). While there remain differences 
in structure and function between rat and human placentas, this model represents a significant step 
in the development of a tractable and reproducible laboratory model of RVFV vertical transmission 
from which findings can merit further investigation in humans. Further, RVFV can infect similar 
placental structures as other arboviruses including ZIKV, West Nile virus and Chikungunya virus 
(107). One of the more surprising findings from McMillen et al. (2018) was the ability of RVFV 
to infect syncytiotrophoblasts in placental explants (10). 
Building off of the foundation of the work done developing the rodent model of RVFV 
congenital infection, the work presented in this thesis represents a continuation of the project, with 
an emphasis on examining the relationship between type III IFNs, known to be constitutively 
expressed at the placenta and RVFV infection in vitro. RVFV and type I IFNs have a dynamic 
relationship, each with the capacity to inhibit the other. Type I IFNs have been known to reduce 
viral titers and even prevent clinical disease in RVFV infection, however, they are also known to 
be detrimental to pregnancy (62, 78).  
The work described in this thesis has been the first to determine the possible effects of type 
III IFNs on RVFV infection. Type III IFNs are known to be constitutively expressed at the placenta 
and can be effective in controlling other congenital arboviral infections like Zika virus both in 
mice and in vitro (66, 67, 86).  
Using HepG2 and BeWo cell lines to mimic target tissues of RVFV infection, in vitro data 
supports the hypothesis that RVFV is sensitive to the effects of type III IFNs. Viral titers were 
reduced in HepG2 cells treated with IFN-λ pre-infection or immediately post-infection, as was also 
the case in IFN-β treated HepG2 cells. These data synergize well with existing literature describing 
HepG2 cells as supportive of viral replication as well as mounting effective type III IFN responses 
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to reduce that viral replication (89, 90). Notably in opposition to the HepG2 data, BeWo cells did 
not experience a reduction in viral titers when treated with IFN-λ regardless of the time of addition. 
This finding speaks to key differences in the cell lines and may also offer clues as to why RVFV 
replication occurs to such a high degree in the maternal-fetal interface, despite the constitutive 
release of IFN-λs during pregnancy.  
Neither cell line experienced significant reduction in viral titers when treated with IFN-λ 
or IFN-β 24 hpi. We hypothesized that this could be due to the action of NSs, a known viral IFN 
antagonist. NSs expression plasmid was able to reduce induction of an IFN-stimulated promoter 
ISRE in HEK-293T cells. Strengthening this finding, mRNA expression levels of key IFN-
stimulated genes (ISGs), previously associated with RVFV infection (PKR, CXCL3 and CXCL8) 
were downregulated in infected HepG2 and BeWo cells as compared to uninfected controls. 
Interestingly, RVFV lacking NSs was also able to downregulate all three ISGs tested, though this 
was partially dependent on cell type and the type of IFN the cells were treated with. PKR and 
CXCL3 were both downregulated in HepG2 and BeWo cells treated with IFN-λ in an NSs-
independent manner. This may point to a role for NSm in inhibiting the ISG response to RVFV, 
as CXCL3 is heavily involved in immune migration which has been shown to be critical in RVFV 
pathogenesis and disease outcome (95). 
CXCL8 expression in both cell lines was reduced in ZH501 infected cells, but was NSs-
dependent, with a partial or full rescue of CXCL8 expression in cell infected with RVFV lacking 
NSs, compared to uninfected controls. This effect was also specific to IFN-β treated cells.  
Further clarifying the role of NSs in inhibiting the innate antiviral response, IFN protein 
production in NSs transfected cells compared to controls was only measurable in HepG2 cells, and 
only IFN-λ production was above the limit of detection. This result points to the fact that BeWo 
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cells do not secrete either IFN after stimulation with poly(I:C) and its effect on IFN production in 
those cells. Lacking better information to inform these findings, two obvious conclusions include 
BeWo cells lacking in stimulation from poly(I:C) despite having a functional TLR3 receptor, or 
that the IFN production response in BeWo cells in dysfunctional in some way. In HepG2 cells, 
IFN-λ production was not affected by the presence of NSs protein or by the concentration of 
poly(I:C) added, however this may be due to the concentrations of poly(I:C) added. A better 
treatment design for the Aim 3 poly(I:C) stimulation experiments would have been a logarithmic 
increase in dose concentration as was the case for the Aim 1 exogenous IFN treatments. Dose 
dependence may have been easier to show using a scale of treatment groups increasing 
successively 0, 10, 100, 1,000 ug/ml poly(I:C) stimulation. As designed, it is difficult to say 
whether a significant increase should be expected in IFN production following a linear increase in 
poly(I:C) stimulation from 0 to 15 ug/ml.  
The investigations described in this thesis highlight the intricate relationship between IFNs 
and RVFV in general, as well as the emerging interactions between RVFV and type III IFNs. In 
sum, these experiments have been able to show that the ability of type III IFNs to inhibit RVFV 
infection and replication is cell type dependent as well as dependent on the time of IFN treatment. 
The role of NSs in mediating differences in type III IFN efficacy against RVFV infection and 
replication remains not well-understood, but these findings suggest NSs or even NSm may be 
playing a role in viral resistance to the effects of IFN-λ in BeWo cells. Indeed, RVFV lacking NSs 
is still able to inhibit ISG expression of PKR, CXCL3 and CXCL8, all ISGs associated with RVFV 
infections, in a cell type dependent and IFN type dependent manner. Finally, there is not enough 
evidence to conclude much about the effect that NSs may have in inhibiting the production of type 
I or III IFN protein from these cell types and more work is needed to identify greater context for 
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the interplay between innate antiviral interferons and Rift Valley fever virus particularly in the 
case of infections at the maternal-fetal interface, which have been shown to be crucial for so many 
viruses causing congenital infections including in the case of Rift Valley fever virus. 
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